VRTX · News · 20260815N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-08-15 · Importance 47 · Surprise 22 · No source text
Vertex Pharmaceuticals reported revenue growth of 12.5% year over year. Reported earnings were $4.73 per share, slightly below analyst estimates. The digest did not provide segment revenue, geographic revenue, or product-mix details.
Key facts
- Vertex Pharmaceuticals reported earnings of $4.73 per share and revenue increased 12.5% year-over-year. source
- Trifecta Capital Advisors LLC purchased 16,745 shares of Vertex Pharmaceuticals valued at approximately $8.318 million. source
- Summit Global Investments purchased 7,182 shares of Vertex Pharmaceuticals in the second quarter valued at approximately $3.57 million. source
- Executives Ourania Tatsis and Duncan Mckechnie sold shares of Vertex Pharmaceuticals. source
- Institutional investors own 90.96% of Vertex Pharmaceuticals' stock. source
- Vertex Pharmaceuticals has seen a 158.2% return over the past five years. source
- Vertex Pharmaceuticals' stock trades at 29.1x earnings. source
- Simply Wall St's fair P/E estimate for Vertex Pharmaceuticals is 28.3x. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +11.1% | Vertex Pharmaceuticals reported earnings of $4.73 per share and revenue increased 12.5% year-over-year. |
| net_income | unclear | realized | — | Vertex Pharmaceuticals reported earnings of $4.73 per share and revenue increased 12.5% year-over-year. |